NYSE:Reata Pharmaceuticals, Inc.

График котировок Reata Pharmaceuticals, Inc.


Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/S 484.85
P/BV 24.29
EV/EBITDA -10.25
EBITDA -0.35
Цена ао 111.93

Основные владельцы

Institutions Объем Доля, %
Cpmg Inc 3063567 8.48
PARAGON Assoc & PARAGON Assoc II JV 150000 0.42
Corriente Advisors, LLC 300000 0.83
SSGA Funds Management Inc 131658 0.36
Guggenheim Funds Distributors, LLC 2 0
Biondo Investment Advisor 36750 0.1
Madden Securities Corporation 43927 0.12
Hennion & Walsh, Inc 100 0
Hartford Funds Management Company, LLC 1793936 4.97
Prosight Management, LP 114554 0.32
GAM Investment Management (Switzerland) AG 40563 0.11
Kennedy Capital Management 35140 0.1
Biondo Investment Advisors, LLC 99602 0.29
Rafferty Asset Management, LLC 2936 0.01
The Variable Annuity Life Insurance Company 84231 0.23
BlackRock Fund Advisors 606254 1.68
Deutsche Asset Management Investment GmbH 151647 0.42
Luther King Capital Management Corporation 22810 0.06
Voya Investments, LLC 59842 0.18
Fidelity Investments 118400 0.33
Columbia Wanger Asset Management LLC 238800 0.66
LBJ Family Wealth Advisors, Ltd 30368 0.08
Deka Investment GmbH 49566 0.14

Содержится в ETF

ETF Доля, % Доходность за год, %
Direxion Daily Pharmaceutical & Medical Bull 3X Shares 4.23 5.39

Похожие компании

Описание Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis. It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of neurological diseases, such as diabetic neuropathy; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), as well as initiated phase 3 Falcon trial for the treatment of ADPKD. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.